X4 Pharmaceuticals Information

We are a fully integrated, commercial-stage biopharmaceutical company driving progress for people living with rare immune disorders. We listen to people whose challenges have been long overlooked, understand their needs, and develop solutions to their most urgent and critical health concerns. Our FDA-approved medication XOLREMDI® (mavorixafor) is commercially available in the U.S. in its first indication. We are evaluating mavorixafor in additional potential indications, and have an ongoing global, pivotal Phase 3 clinical trial for its use in chronic neutropenia. Our corporate headquarters is in Boston, Massachusetts.